Dr. Li Jianwei (李建伟) joined our Group on October 14, 2020 and served as our chief technology officer and the chief operating officer of Cellularforce from October 2020 to February 2023. He served as the chief operating officer and deputy general manager of our Company and general manager of Cellularforce from March 2023 to December 2024. Since December 2024, Dr. Li Jianwei has served as the deputy general manager of the company, mainly responsible for the daily affairs of the General Office of the Group.

Dr. Li has around 20 years of experience in biotechnology and pharmaceutical industries. Prior to joining our Group, he once worked at Symyx Technologies Inc., a company mainly engaged in developing high-throughput technologies for screening catalysts and API leads whose shares are listed on NASDAQ (stock code: SMMX), and Syagen Technology Inc., a subsidiary of Smiths Group plc, a company mainly engaged in developing portable mass spectrometers for fast field detection of bio-organic weapons and drugs whose shares are listed on the London Stock Exchange (stock code: SMIN). From August 2007 to November 2014, Dr. Li served as the principal scientist at Allergan, Inc. (currently known as AbbVie Inc.), a global pharmaceutical company whose shares are listed on NASDAQ (stock code: ABBV). From April 2016 to August 2020, Dr. Li served as a vice president of process development and manufacturing department at Sorrento Therapeutics Inc., a clinical-stage antibody-centric biopharmaceutical company whose shares are listed on NASDAQ (stock code: SRNE).

Dr. Li graduated from Shanghai University of Technology (上海工業大學) (currently known as Shanghai University (上海大學)) in the PRC with a bachelor’s degree in metallurgical analysis in July 1982 and a master’s degree in applied chemistry in May 1988. He further received his Ph.D. degree in science from University of Berne in Switzerland in December 1993.